Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials

Martin Schulz,George Bashirians, Seng H. Cheng,Daniel I. Levy, Mark Lundie, Lisa Wilcox,Ian Winburn,Suryanarayan Somanathan

MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT（2023）

引用 0|浏览0

暂无评分

摘要

Pre-existing anti-adeno-associated virus (AAV) antibodies can impede successful gene transfer and potentially have safety consequences for patients receiving recombinant AAV (rAAV)-mediated gene therapy (GTx). Hence, assessing patients’ anti-AAV antibody status is an important consideration prior to systemic rAAV GTx administration.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要